NovoSeven

NovoSeven�Coagulation Factor VIIa (Recombinant ) is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX. NovoSeven� is the only recombinant FVIIa for effective, reliable treatment of bleeding episodes. Its unique mechanism of action induces hemostasis independently of FVIII and FIX.

When complexed with tissue factor, NovoSeven� can activate Factor X to Factor Xa, as well as hemostatic plug by converting fibrinogen to fibrinand thereby inducing local hemostasis.

NovoSeven contains trace amounts of proteins derived from the manufacturing and purification processes such as mouse IgG (maximum of 1.2 ng/mg), bovine IgG (maximum of 30 ng/mg), and protein from BHK-cells and media (maximum of 19 ng/mg).